Trial Profile
Phase III, open-label, multi-center study to assess the pharmacodynamic (PD), pharmacokinetic (PK) and safety of Zoreline 10.8 mg goserelin subcutaneous implant (Novalon) in male patients with prostate cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Feb 2017
Price :
$35
*
At a glance
- Drugs Goserelin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacodynamics
- Sponsors Novalon Pharmaceuticals
- 10 Feb 2017 New trial record